Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis
TORONTO, ON / ACCESSWIRE / September 9, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that through its subsidiary, HUGE Biopharma Australia Pty Ltd., it entered into an agreement with Ingenu CRO Pty Ltd on August 13, 2024 to conduct a clinical study to observe and quantify disease progression in patients with primary progressive multiple sclerosis. This study will facilitate a future phase 2 clinical trial with Lucid-21-302 (Lucid-MS).
安大略省多倫多/ACCESSWIRE/2024年9月9日/致力於建立創新資產和生物技術解決方案組合的生物製藥公司量子生物製藥有限公司（納斯達克股票代碼：QNTM）（FRA: 0K91）（「Quantum BioPharma」 或 「公司」）今天宣佈，它通過其子公司HUGE Biopharma Australia Pty Ltd.（納斯達克股票代碼：QNTM）（FRA: 0K91）（「量子生物製藥」 或 「公司」）今天宣佈，它通過其子公司HUGE Biopharma Australia Pty Ltd. 2024年8月13日與Ingenu CRO Pty Ltd達成協議，進行一項臨床研究，以觀察和量化原發性進行性多發性硬化症患者的疾病進展。這項研究將促進未來使用Lucid-21-302（Lucid-MS）進行2期臨床試驗。
"We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research program and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302," said Dr. Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum Biopharma.
「我們很高興與Ingenu CRO合作，對多發性硬化症患者進行這項觀察性研究。這是一項重要的研究，它推進了我們的多發性硬化症研究計劃，使我們更接近啓動Lucid-21-302的2期臨床試驗。」 Quantum Biopharma負責科學和臨床事務的副總裁安德烈·赫魯辛斯基博士說。
Contact Information
聯繫信息
Zeeshan Saeed
Founder, CEO and Executive Co-Chairman of the Board
zsaeed@quantumbiopharma.com
416-854-8884
Zeeshan Saeed
創始人、首席執行官兼董事會執行聯席主席
zsaeed@quantumbiopharma.com
416-854-8884
SOURCE: Quantum Biopharma Ltd.
來源：量子生物製藥有限公司
譯文內容由第三人軟體翻譯。